Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews.
Research Areas Include:
? All major diseases of the lung
? Physiology
? Pathology
? Drug delivery
? Metabolism
? Pulmonary Toxicology.
《Pulmonary Pharmacology & Therapeutics》是一本由ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD出版商出版的專業醫學期刊,該刊創刊于1997年,刊期Bimonthly,該刊已被國際權威數據庫SCIE收錄。在中科院最新升級版分區表中,該刊分區信息為大類學科:醫學 3區,小類學科:藥學 3區;呼吸系統 3區;在JCR(Journal Citation Reports)分區等級為Q3。該刊發文范圍涵蓋藥學等領域,旨在及時、準確、全面地報道國內外藥學工作者在該領域取得的最新研究成果、工作進展及學術動態、技術革新等,促進學術交流,鼓勵學術創新。2021年影響因子為3.282,平均審稿速度較慢,6-12周。
大類學科 | 分區 | 小類學科 | 分區 | Top期刊 | 綜述期刊 |
醫學 | 3區 | PHARMACOLOGY & PHARMACY 藥學 RESPIRATORY SYSTEM 呼吸系統 | 3區 3區 | 否 | 否 |
JCR分區等級 | JCR所屬學科 | 分區 | 影響因子 |
Q3 | PHARMACOLOGY & PHARMACY | Q3 | 3.282 |
RESPIRATORY SYSTEM | Q3 |
影響因子 | h-index | Gold OA文章占比 | 研究類文章占比 | OA開放訪問 | 平均審稿速度 |
3.282 | 66 | 15.17% | 80.65% | 未開放 | 較慢,6-12周 |